Overview
- Multiple outlets reported Friday that Sun Pharma submitted a binding $12 billion all-cash proposal for Organon after more than three months of due diligence.
- The Indian company was reported to be arranging funding with JPMorgan and Japan’s MUFG to support the potential deal.
- Organon’s New York–listed shares jumped 18% Thursday then 41% Friday to about $8.25, while Sun Pharma fell roughly 3–5% on the Mumbai exchange.
- Sun Pharma told the Bombay Stock Exchange the media reports were speculative and that no material event required disclosure under listing rules.
- If completed, the transaction would rank among the biggest overseas buys by an Indian drugmaker and would add a global women’s health and biosimilars portfolio, though Organon carries about $9 billion of debt and posted $6.2 billion in 2025 sales.